Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03551782
Title A Study of JNJ-63723283, a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

prostate adenocarcinoma

Therapies

Apalutamide + Cetrelimab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN | BEL


No variant requirements are available.